Silver Book Fact

Macugen to treat wet age-related macular degeneration (AMD)

A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.

Gragoudas E, Adamis A, Cunningham E, Feinsod M, et al. Pegaptanib for Neovascular Age-Related Macular Degeneration. NEJM. 2004; 351(27): 2805-16. http://content.nejm.org/cgi/content/abstract/351/27/2805

Reference

Title
Pegaptanib for Neovascular Age-Related Macular Degeneration
Publication
NEJM
Publication Date
2004
Authors
Gragoudas E, Adamis A, Cunningham E, Feinsod M, et al.
Volume & Issue
Volume 351, Issue 27
Pages
2805-16
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • DR Treatment Savings in the US
    Every year, the U.S. saves an estimated $1.6 billion by treating DR.  
  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of 94,304 person-years of sight.  
  • Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections  
  • DR Treatment Reduced Risk of Blindness
    Appropriate treatment can reduce the risk of blindness or moderate vision loss from DR by more than 90%.  
  • Studies of patients with myocardial infarction found that warfarin reduced stroke risk compared to placeboby 40% to 55%.